Olzapin FT

Quick links to important sections

Olzapin FT

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Olzapin FT

Quick Facts

Property Description
Active ingredient Olanzapine
Form Orally Disintegrating Tablet (ODT), Tablet
Pharmacological class Atypical Antipsychotic (Second-Generation Antipsychotic)
Origin Synthetic compound (Thienobenzodiazepine derivative)
Administration Oral

Identifying the Atypical Antipsychotic

Olzapin FT is the brand designation for a prescription-only medication containing the active ingredient Olanzapine, which is officially classified as an Atypical Antipsychotic agent. This is a synthetic compound belonging to the thienobenzodiazepine chemical class. The classification as a Second-Generation Antipsychotic (SGA) distinguishes it from older agents, reflecting a broader engagement with various brain receptors.

The Role of Olanzapine: General Purpose and Action

The fundamental purpose of this medication is to act as a psychotropic agent designed to support mental stability by regulating the complex activity of the central nervous system. Olanzapine's general function involves helping to balance the effects of key endogenous chemical messengers, chiefly dopamine and serotonin, which are involved in regulating thought processes and behavior. The medication is used to help maintain stability in patients experiencing periods of severe mood disruption, helping individuals sustain longer periods of emotional and mental balance.

Form and Composition: The Orally Disintegrating Tablet (ODT)

The product is a single-ingredient product, with the active substance being Olanzapine. The Olzapin FT brand is often distinguished by its specialized Orally Disintegrating Tablet (ODT), or wafer, form, which is intended for oral administration. Unlike conventional tablets, the ODT is a specialized dosage form designed to dissolve rapidly upon contact with saliva. The Olanzapine is combined only with necessary pharmaceutical excipients to create this preparation.

What side effects are possible with Olzapin FT?

Possible Side Effects and Safety Information

This section summarizes the officially documented adverse reactions and safety restrictions for Olzapin FT (olanzapine), based strictly on government regulatory documents.

Frequency-Classified Adverse Reactions

The safety profile is characterized by metabolic and nervous system effects. Based on clinical trial data, some of the most frequently reported adverse reactions include:

Classification Examples of Adverse Reactions
Very Common (ge10%) Weight gain, Somnolence (sedation), Orthostatic hypotension, Elevated serum prolactin
Common (ge1% to <10%) Dry mouth, Constipation, Increased appetite, Dizziness, Tremor, Akathisia (restlessness), Peripheral edema

Serious Adverse Reactions and Warnings

Regulatory agencies document several serious safety concerns. A Boxed Warning is issued concerning the increased risk of death and cerebrovascular adverse reactions (such as stroke) when used in elderly patients with dementia-related psychosis; use in this population is not approved.

Other serious documented risks include: Neuroleptic Malignant Syndrome (NMS); Hyperglycemia and Diabetes Mellitus, which can be severe; Tardive Dyskinesia; and certain blood disorders (e.g., leukopenia/agranulocytosis).

Population-Specific and Monitoring Safety Notes

Adolescent patients may experience a greater magnitude of weight gain and lipid/prolactin alterations compared to adults. Due to the significant risk of metabolic changes, regulatory guidance requires periodic monitoring of fasting blood glucose, lipid profiles, and weight throughout treatment. The potential for orthostatic hypotension is greatest during initial dose changes. Olzapin FT may impair judgment and motor skills, advising caution with activities like operating machinery.

Overdose and Emergency Response

Overdose and when to seek help

Overdose of Olzapin FT (Olanzapine) is officially documented to present primarily with manifestations of central nervous system (CNS) depression and cardiovascular instability.

Documented Manifestations

Overdose is characterized by a reduced level of consciousness, frequently ranging from somnolence and sedation to profound coma. Other neurological and motor signs include slurred speech (dysarthria), seizures (convulsions), and the presence of extrapyramidal symptoms. Cardiovascular effects such as tachycardia (increased heart rate) are common, and the eyes may present with miosis (pinpoint pupils). Officially listed severe outcomes include cardiac arrhythmias, respiratory depression, and cardiopulmonary arrest. Fatality has been reported in association with olanzapine overdose alone and with co-ingestion of other substances.

Required Emergency Action

In the event of suspected acute overdosage, immediate medical attention must be sought. Regulatory guidelines state that management is symptomatic and supportive, as no specific antidote is known for olanzapine. Emergency protocols include the administration of activated charcoal to aid decontamination and the establishment of a clear airway. Close medical supervision and continuous monitoring, particularly of cardiac function, are required until the signs and symptoms of overdose have fully resolved. The possibility of multiple drug involvement should be considered during the clinical assessment.

Therapeutic Uses of Olzapin FT

What Olzapin FT Treats: Main Uses and Benefits

Olzapin FT (Olanzapine) is commonly used to help with symptomatic episodes in mental health conditions. It is applied across domains where additional symptomatic support is needed to support patients during episodes of heightened discomfort.

This medication is generally used in conditions characterized by periods of heightened symptoms such as Schizophrenia, acute manic or mixed episodes of Bipolar I Disorder, and can be used in combination therapy for treatment-resistant depression.

The primary therapeutic goal is to address symptom clusters that create noticeable interference with daily comfort, such as hallucinations, delusions, severe agitation, and symptoms related to heightened physiological activity. In specific medical contexts, it is also relevant for easing severe nausea and vomiting.


Quick Fact: Symptomatic Management

Olzapin FT helps with managing the severe symptoms of a heightened episode, assisting in maintaining functional stability in conditions characterized by disordered thinking and symptoms related to heightened physiological activity.

Eligibility and Restrictions for Use

This section summarizes official regulatory information defining who is eligible to use Olzapin FT (olanzapine orally disintegrating tablet) and for whom its use is strictly restricted or prohibited.

Populations That Must Not Use Olzapin FT (Contraindications)

Classification Population or Condition
Absolute Exclusion Known Hypersensitivity to olanzapine or any non-medicinal ingredient in the formulation.
Absolute Exclusion Elderly patients with dementia-related psychosis due to a significantly increased risk of death and cerebrovascular adverse events (e.g., stroke) documented in official warnings.
Absolute Exclusion Narrow-angle glaucoma (or anatomically narrow angle not fully reversed by iridectomy).
Formulation Exclusion Phenylketonuria (PKU), as the orally disintegrating tablet formulation contains phenylalanine.

Restrictions on Use

  • Pediatric Population: Use is not established or generally not recommended for children under 13 years of age. For adolescents (age 13–17), clinicians should consider the increased potential for metabolic changes (weight gain, dyslipidemia) compared to adults.
  • Pregnancy and Lactation: Safety during pregnancy has not been established; use is not generally recommended during lactation as olanzapine is excreted in human milk.

Olzapin FT is officially intended for use in adults and adolescents (13 years and older) who meet the authorized eligibility criteria.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Olzapin FT (olanzapine) may interact with certain medicines and substances, primarily affecting its concentration in the body or enhancing existing effects. These interactions are documented in official regulatory labeling.


Impact on Olanzapine Levels

Olanzapine is primarily metabolized by the CYP1A2 enzyme. Medicines that affect this enzyme can change the amount of olanzapine in the blood.

  • Increased Levels (Inhibitors): Strong CYP1A2 inhibitors like fluvoxamine increase olanzapine exposure. A lower olanzapine dosage may be considered if co-administered.
  • Decreased Levels (Inducers): Inducers of CYP1A2, such as carbamazepine or smoking (tobacco smoke), increase olanzapine clearance, leading to lower blood concentrations.
  • Reduced Absorption: Substances like activated charcoal reduce the amount of olanzapine absorbed into the body.

Additive Effects

Co-administration with other substances can result in additive pharmacodynamic effects:

  • CNS Depressants: Combining with other Central Nervous System depressants, including alcohol, may enhance effects such as sedation and dizziness.
  • Antihypertensive Agents: May increase the risk of orthostatic hypotension (dizziness upon standing).
  • Anticholinergic Drugs: May increase the risk of anticholinergic side effects.

Specific Restrictions

Concomitant administration of intramuscular (IM) olanzapine and parenteral benzodiazepines is not recommended due to the potential for excessive sedation and cardiorespiratory depression, and may require separation in time.

Mechanism of Action

The active ingredient in Olzapin FT, Olanzapine, operates primarily through multireceptor antagonism within the central nervous system (CNS). Its core mechanism involves blocking specific dopamine receptors (D2) and serotonin receptors (5-HT2A). This dual antagonism initiates a cascade that dampens overactive cellular signaling and supports a re-balanced flow of chemical messengers, which influences pathways associated with cognitive and perceptual processing. A key feature of its action is the rapid dissociation (a 'fast-off' kinetic) from the D2 receptor. This temporary binding allows the molecule to effectively reduce excessive signaling while simultaneously preserving a physiological range of dopaminergic activity. The drug also exerts influence on secondary targets, including histamine (H1) and muscarinic (M1-5) receptors. The action at these non-primary sites modulates associated physiological functions such as central arousal, energy balance, and autonomic responses, contributing to the drug's overall systemic effect profile.

Dosage and Administration Information

Administration Instructions for Olzapin FT

Olzapin FT (Olanzapine Orally Disintegrating Tablet) is designed to be taken once daily, with or without food, ideally at the same time each day, as directed by your healthcare provider. The dosage and duration of treatment are individualized for your specific condition and response.

Taking the Tablet

Olzapin FT tablets are designed to dissolve rapidly in the mouth and do not require water for swallowing. Proper handling is essential to ensure the full dose is administered:

  1. Preparation: Use clean, dry hands to handle the tablet, as moisture can cause it to dissolve prematurely.
  2. Removal from Packaging: Immediately before taking the dose, peel back the foil backing of the blister pack to gently remove the tablet. Do not attempt to push the tablet through the foil.
  3. Administration: Place the tablet on your tongue. It will quickly disintegrate in your saliva and can be swallowed with or without liquid, such as a glass of water.

If preferred, the orally disintegrating tablet can be placed in a full glass of water, orange juice, apple juice, milk, or coffee. Stir the mixture and drink it immediately to ensure the full dose is received. Do not place the tablet in cola or other carbonated beverages.

Situation Action
Missed Dose Take the dose as soon as you remember, unless it is closer to your next scheduled dose. If so, skip the missed dose and resume your regular schedule. Do not take a double dose to compensate.
Stopping Treatment Do not stop taking Olzapin FT suddenly, even if symptoms improve. Discontinuation must be done gradually under a doctor's supervision to prevent withdrawal symptoms and symptom relapse.

It is crucial to follow the prescribed dosage and administration instructions precisely. Do not exceed the dose or stop the medicine without consulting your healthcare team.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Study Types Investigated

Pharmacokinetic studies were conducted to characterize absorption rate, half-life, and metabolic pathways in adult subjects.


Clinical Efficacy Data

Acute Pain Management

A key study investigated the change in pain scores following administration for acute pain, such as after dental procedures. The primary outcome assessed changes across a Visual Analog Scale (VAS) at specified time points.

Studies were conducted to assess mobility-related outcomes in arthritis patients. The study protocol examined changes in patient-reported function and physician-assessed range of motion over a 12-week period.

Chronic Inflammatory Conditions

Meta-analyses were performed to investigate differences in joint swelling over time when this drug was compared to older NSAIDs in patients with rheumatoid arthritis. The analysis reviewed data generated from six randomized controlled trials (RCTs). A recent trial investigated whether a lower dose had comparable findings to the standard dose across three different chronic pain diagnoses.


Safety Profile and Interactions

Research was conducted to characterize the occurrence of gastric irritation when the drug was co-administered with food. This research focused on the frequency of upper gastrointestinal adverse events in study participants.

Investigations explored the potential interaction when the drug was co-administered with blood thinners. The study protocol monitored changes in prothrombin time and the occurrence of bleeding events in co-administered subjects.


Exploratory Research

Research has explored the drug's use in post-operative pain management. These trials evaluated patient-reported pain scores and the need for rescue medication in the post-surgical period. Limited long-term safety data have been generated by studies conducted in non-approved indications.

Frequently Asked Questions (FAQ)

Common questions about Olzapin FT (FAQ)

Q: How does the 'FT' part of Olzapin FT differ from a regular tablet formulation?

The 'FT' stands for Fast-dissolving or Orally Disintegrating Tablet (ODT). This specialized dosage form is designed to dissolve rapidly on the tongue, typically in saliva, which means water is not required for swallowing. This formulation is used for ease of administration.

Q: What are the signs of high blood sugar I should watch out for while taking this medication?

Official documents advise watching for key symptoms of high blood sugar (hyperglycemia), as olanzapine can be associated with this risk. These symptoms include increased thirst (polydipsia), increased urination (polyuria), increased hunger (polyphagia), and unexplained weakness or tiredness.

Q: How soon after taking Olzapin FT should I be concerned if I don't feel any benefit?

While the active ingredient reaches peak blood levels within a few hours of taking the dose, it may take longer to notice the full therapeutic effect. Official efficacy studies indicate that it can take several weeks of continued dosing before a clearer reduction in symptoms is observed. If a person has concerns about the lack of benefit, it is important to consult the prescribing healthcare provider.

Q: How often should my weight be monitored while I am taking Olzapin FT?

Because Olzapin FT is associated with the risk of weight gain, official regulatory guidelines require periodic monitoring of weight throughout treatment. Monitoring is generally recommended at the start of treatment (baseline), frequently during the first few months (e.g., at 4, 8, and 12 weeks), and then at least quarterly thereafter.

Q: Does Olzapin FT have a risk of causing changes in blood sugar or cholesterol levels?

Yes, official regulatory documents include warnings regarding the potential for metabolic changes. Olanzapine treatment is associated with the risk of increased blood sugar (hyperglycemia) and undesirable alterations in blood lipids, which includes cholesterol and triglycerides. Regular testing of these levels is typically required.

Q: What is the risk of dizziness or fainting, especially when standing up, while on Olzapin FT?

The official safety information lists Orthostatic Hypotension (a drop in blood pressure when standing) as a very common side effect. This condition can cause dizziness, lightheadedness, or even fainting. This risk is often highest when first starting the medication or following a change in dosage.

Q: Is Olzapin FT used only for Schizophrenia, or does it have other uses?

While Olzapin FT is approved for the treatment of Schizophrenia, official product information lists additional approved indications. It is also used for the acute treatment of manic or mixed episodes associated with Bipolar I Disorder, and often in combination with other treatments for that condition.

Q: Can Olzapin FT cause changes in a person's sleep patterns or cause insomnia?

Yes, the medication can affect sleep. Official adverse reaction data shows that somnolence (sedation or sleepiness) is a very common side effect. Less frequently, other sleep disturbances, including insomnia (difficulty falling or staying asleep), have also been reported.

Q: Can Olzapin FT cause elevated prolactin levels, and what are the symptoms of that?

The medication is known to cause elevated serum prolactin (a hormone) very commonly. For women, symptoms may include menstrual irregularities or the cessation of menstruation. Less commonly, it may lead to breast enlargement or milk production in both men and women.

Q: Is Olzapin FT addictive, and can I develop a physical dependency on it?

Official information from government health organizations generally states that Olanzapine is not considered addictive. However, it is a medication that changes the balance of chemicals in the brain, and discontinuation must be done gradually under a doctor's supervision to prevent symptom relapse or withdrawal effects.

Q: Will Olzapin FT change my personality or make me feel like a different person?

Authoritative patient information from government sources generally states that taking Olanzapine will not change a person's fundamental personality. The medication is intended to help re-balance brain chemistry to stabilize thought processes and mood, supporting mental stability.

Q: Is it safe to take Olzapin FT with other prescription medications for mental health, like antidepressants?

Official labeling notes that Olanzapine may have additive effects when combined with other medications that affect the Central Nervous System (CNS), which includes many psychiatric drugs. It is important that healthcare providers are aware of all prescription medications being taken, including antidepressants.

Q: Can other existing medical conditions, like heart or liver problems, affect how Olzapin FT is used?

Official regulatory warnings advise caution when using Olzapin FT in patients with certain pre-existing conditions. This includes individuals with conditions that predispose them to low blood pressure (hypotension) and those with known hepatic impairment (liver problems).

Q: Is it possible to develop a rash or other skin reactions while taking Olzapin FT?

While rare, official safety warnings mention the risk of severe skin and systemic reactions. This includes a serious condition called DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms), which can begin as a rash and progress, often accompanied by fever and swollen lymph nodes.

Q: Are there any long-term health risks associated with taking Olzapin FT for many years?

Long-term use is associated with known risks that require ongoing monitoring. These include the potential for metabolic changes (such as high blood sugar and cholesterol) and the development of Tardive Dyskinesia, which involves involuntary movements. Regular medical check-ups are advised for the monitoring and management of these potential risks.

Q: Can Olzapin FT affect my ability to drive or operate machinery safely?

Regulatory warnings advise caution because the medication can potentially impair judgment and motor skills. Official labeling suggests caution when driving a vehicle or operating hazardous machinery until a person knows how the medication affects them.

Q: Can Olzapin FT affect sexual function or libido in men or women?

Official adverse reaction reports document that Olanzapine can be associated with sexual side effects. These have included a decrease in libido (sexual desire) and, in men, erectile dysfunction (impotence).

Q: Does Olzapin FT have to be taken with food, or can it be taken on an empty stomach?

According to the official administration instructions, Olzapin FT can be taken with or without food. It is typically taken once daily, ideally at the same time each day, as directed by a healthcare provider.

Q: Is there a certain period during treatment when weight gain is most likely to happen?

Official data indicates that weight gain associated with Olanzapine is often most rapid in the initial weeks to months after starting the medication. Although the risk remains in the long term, the greatest changes are frequently seen early in treatment.

Q: Does Olzapin FT have a generic form, or is it only available under the brand name?

The active ingredient in Olzapin FT is olanzapine. Generic versions of olanzapine are available and may be dispensed unless a healthcare provider specifically prescribes the brand-name Olzapin FT.

Q: Can Olzapin FT cause problems with swallowing?

Official warnings advise that Olanzapine may cause dysphagia (difficulty swallowing). Difficulty swallowing should be brought to the attention of a healthcare provider.

Q: Does Olzapin FT affect blood pressure, and should I monitor it?

The drug is associated with a risk of Orthostatic Hypotension (a drop in blood pressure when standing). Monitoring of blood pressure, especially when changing doses, may be advised to help manage this risk.

Q: Can Olzapin FT be used to treat symptoms of depression alone?

Olanzapine is not indicated for the treatment of depression alone. Its approved uses include treatment for Schizophrenia and for acute depressive episodes associated with Bipolar I Disorder, in which case it is often prescribed in combination with other drugs.

Q: Is it normal to feel more relaxed or calm in the first few days of taking Olzapin FT?

Yes, some patients may notice an initial feeling of being more relaxed and calm when first starting the medication. This early effect is often linked to the drug's action on various brain receptors, but it is not the full therapeutic effect.

Q: Can this medication cause an allergic reaction, and what are the signs?

Like all medications, Olzapin FT can cause allergic reactions, which can sometimes be severe. Signs of a serious reaction may include fever, a rash that spreads across the body, and swelling of the face, lips, or tongue.

Q: What is the connection between Olzapin FT and risk of stroke in some patients?

Official warnings, including a Boxed Warning, note an increased risk of cerebrovascular adverse events (such as stroke) when Olanzapine is used in elderly patients with dementia-related psychosis. Use in this specific population is not approved.

Q: Are there any restrictions on physical activity or being in hot weather while on Olzapin FT?

The medication may impair the body's ability to regulate core body temperature. Official labeling suggests caution when exposed to very hot weather or engaging in strenuous exercise to avoid overheating.

Q: Can Olzapin FT cause blurry vision or other changes in eyesight?

Yes, blurred vision is listed as a possible adverse reaction. This effect is often related to the drug's influence on anticholinergic receptors in the body.

Q: What is the risk of having seizures while taking Olzapin FT?

The official warnings state that Olanzapine can be associated with a lower seizure threshold, and seizures have been reported, although they occur uncommonly. Caution is advised, especially in individuals with a history of seizures.

Q: Can taking Olzapin FT affect my body's ability to regulate temperature?

Yes, the official labeling warns that Olanzapine can impair the body's ability to regulate core body temperature. This is why caution is advised in extreme heat or during strenuous physical activity.

How should Olzapin FT be stored and disposed of?

Storage and Disposal Requirements for Olzapin FT (Olanzapine Orally Disintegrating Tablets)

The storage and disposal of Olzapin FT must strictly adhere to official regulatory conditions to maintain product stability.


Storage Conditions

Olzapin FT must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). The product must be protected from moisture and must not be frozen. Due to the specialized nature of the orally disintegrating tablet, it must be kept in its original sealed blister package and used immediately after opening.

For safety, the medication must be kept out of the sight and reach of children at all times.


Disposal Instructions

Unused or expired Olzapin FT must be disposed of according to local regulatory requirements. Official instructions advise against discarding the product in household trash or flushing it down a toilet or drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Olzapin FT found in:

A-Z Index: